Stockscreener 앱 받기
0.206
34.08%
-0.1065
시간 외 거래:
.21
0.004
+1.94%
전일 마감가:
$0.3125
열려 있는:
$0.335
하루 거래량:
6.69M
Relative Volume:
0.64
시가총액:
$10.20M
수익:
-
순이익/손실:
-
주가수익비율:
-
EPS:
-
순현금흐름:
-
1주 성능:
-52.42%
1개월 성능:
-64.19%
6개월 성능:
-64.64%
1년 성능:
+0.00%
1일 변동 폭
$0.2012
$0.335
1주일 범위
$0.2012
$0.4498
52주 변동 폭
$0.2012
$2.10
Aspire Biopharma Holdings Inc Stock (ASBP) Company Profile
명칭
Aspire Biopharma Holdings Inc
전화
561-704-8527
주소
194 CANDELARO DRIVE, #233, HUMACAO
ASBP을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ASBP
Aspire Biopharma Holdings Inc
|
0.206 | 15.48M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
391.64 | 101.35B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
456.00 | 58.66B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
562.27 | 59.43B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
737.56 | 44.01B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
340.70 | 36.56B | 3.81B | -644.79M | -669.77M | -6.24 |
Aspire Biopharma Holdings Inc 주식(ASBP)의 최신 뉴스
Is There Hidden Value in Modern Engineering and Projects Limiteds Business ModelQuarterly Earnings Review & Double Digit Trading Ideas - earlytimes.in
What drives Aspire Biopharma Holdings Inc Equity Warrant stock priceCandlestick Trading Patterns & Best Stocks For Explosive Growth - earlytimes.in
What analysts say about Aspire Biopharma Holdings Inc stockShort-Term Trading Alerts & Free Powerful Profit Generation - earlytimes.in
What analysts say about Aspire Biopharma Holdings Inc Equity Warrant stockResistance Zone Identification & Register for the Next Free Workshop - earlytimes.in
How Star Equity Holdings Inc. (FDV0) stock trades after earningsIPO Watch & Reliable Breakout Forecasts - newser.com
Aspire Biopharma Holdings Inc Stock Analysis and ForecastPrice-to-Earnings Ratio Insights & Minimal Investment Capital - earlytimes.in
Aspire Biopharma Holdings Inc Equity Warrant Stock Analysis and Forecast - earlytimes.in
Aspire Biopharma completes $1 million funding tranche and changes auditor - Investing.com
Aspire Biopharma Announces Breakthrough Final Results from Clinical Trial of Investigational New Sublingual Aspirin Product for Treatment of Suspected Acute Myocardial Infarction (Heart Attack) - Detroit Free Press
Aspire Biopharma Holdings, Inc. Announces CEO Transition - Foster's Daily Democrat
Aspire Biopharma files to sell 147.18M shares of common stock for holders - MSN
Aspire Biopharma Enlists Fitness Influencers To Promote Pre-Workout Product - Net Influencer
Aspire Biopharma secures initial order for preworkout supplement, part of agreement with SupraNatural - MSN
Aspire Biopharma Holdings Inc (NASDAQ: ASBP) 8.11% Incline Turns Away Investor Interest In Company’s Stock - stocksregister.com
Aspire Biopharma Engages Well-Known Athletes and Influencers to Accelerate Consumer Awareness and Sales of its BUZZ BOMB(TM) Sublingual Caffeine Pre-Workout Product - ACCESS Newswire
Aspire Biopharma Engages Well-Known Athletes and Influencers to Accelerate Consumer Awareness and Sales of its BUZZ BOMB(TM) Sublingual Caffeine Pre-Workout Product | FinancialContent - FinancialContent
Aspire Biopharma Announces Initial Production Order of Two Million Servings (100,000 20-packs) of BUZZ BOMB(TM) Pre-Workout Supplement - ACCESS Newswire
2 Million Unit Production Order: Aspire Biopharma Scales BUZZ BOMB Pre-Workout in $27.9B Market - Stock Titan
Aspire Biopharma Holdings, Inc. Unveils E-commerce Platform, Launches with its BUZZ BOMB Pre-Workout Supplement - Fall River Herald News
Can volume confirm reversal in NCR Voyix CorporationEarnings Overview Report & Safe Investment Capital Preservation Plans - newser.com
Aspire Biopharma Holdings, Inc., Announces Last Patient Dosed in Phase 1 Clinical Trial of its Oral Transmucosal Fast-Acting High-Dose Aspirin Formulation - The Florida Times-Union
Aspire Biopharma Holdings, Inc. to Launch its BUZZ BOMB Pre-Workout Supplement at FitCon and FitExpo, Two of the Largest Fitness Conventions in the World - The Florida Times-Union
Aspire Biopharma Reports Final Results in Sublingual Aspirin Trial for Heart Attack Treatment; Shares Fall Pre Bell - MarketScreener
2-Minute Response Time: Aspire's New Sublingual Aspirin Could Revolutionize Heart Attack Treatment - Stock Titan
PRN_FinancialWrapper - FinancialContent
How to track smart money flows in Banc of California Inc.Weekly Profit Report & Daily Volume Surge Trade Alerts - Newser
Risk vs reward if holding onto Theravance Biopharma Inc.Weekly Investment Recap & Fast Moving Market Watchlists - Newser
How to track smart money flows in aTyr Pharma Inc.2025 Price Targets & Free Real-Time Volume Trigger Notifications - Newser
ExlService Holdings Inc. stock chart pattern explainedTrade Exit Summary & Free Safe Entry Trade Signal Reports - Newser
Combining price and volume data for Shell plc Depositary ReceiptEarnings Risk Summary & Technical Buy Zone Confirmation - Newser
Aspire Biopharma Secures $9.7M Through Securities Agreement - MSN
How to track smart money flows in TTEC Holdings Inc.2025 Fundamental Recap & AI Based Buy and Sell Signals - Newser
Historical volatility pattern of Zoomcar Holdings Inc. visualizedJuly 2025 Trends & Precise Swing Trade Entry Alerts - Newser
What earnings revisions data tells us about Newton Golf Company Inc.July 2025 News Drivers & Real-Time Buy Signal Alerts - Newser
Risk vs reward if holding onto Edesa Biotech Inc.2025 Market Trends & Risk Adjusted Swing Trade Ideas - Newser
What MACD and RSI say about CHSNWeekly Trend Summary & Advanced Swing Trade Entry Alerts - Newser
Aspire Biopharma enters $9.7 million note purchase agreement with investors By Investing.com - Investing.com Nigeria
Aspire Biopharma's Debt Refinancing: A Strategic Play for Biotech Capital Structure Optimization and Operational Flexibility - AInvest
Aspire Biopharma Holdings, Inc. Building a Base Near Support2025 Retail Activity & Weekly Setup with High ROI Potential - thegnnews.com
Promising Penny Stocks To Consider – August 18th - Defense World
Aspire Biopharma Plummets 22.7%: E-Commerce Launch Volatility and Technical Divergence Spark Turbulence - AInvest
Aspire Biopharma Announces Positive Top-Line Results from Clinical Trial of Investigational New Sublingual Aspirin Product for Treatment of Suspected Acute Myocardial Infarction (Heart Attack) - BioSpace
Penny Stocks on the Move: Today’s Top Gainers and Biggest Decliners - AInvest
Aspire Shares Are Trading Higher Monday: What's Going On?Aspire Biopharma Hldgs (NASDAQ:ASBP) - Benzinga
Crude Oil Moves Higher; US Homebuilder Sentiment Declines In August - Benzinga
Aspire Biopharma Holdings shares surge 67.69% intraday after positive clinical trial results for sublingual aspirin product. - AInvest
US Stocks Mixed; Riskified Shares Dip After Q2 Results - Benzinga
Breakthrough Heart Attack Treatment: Sublingual Aspirin Shows Superior Results in Aspire Biopharma Trial - Stock Titan
Aspire Biopharma Holdings Inc (ASBP) 재무 분석
Aspire Biopharma Holdings Inc (ASBP)에 대한 금융 데이터가 없습니다. 더 많은 정보를 위해 다른 주식을 확인해보세요.
매출
순이익
현금흐름
주당 순 이익
2.36%
1.10%
자본화:
|
볼륨(24시간):